Patents by Inventor Songzhe HAN

Songzhe HAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • EGFR DEGRADERS AND METHODS OF USE
    Publication number: 20240165243
    Abstract: Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
    Type: Application
    Filed: February 9, 2022
    Publication date: May 23, 2024
    Inventors: Bailin LEI, Huaqing LIU, Songzhe HAN, Zhiwei WANG
  • EGFR Degraders and Associated Methods of Use
    Publication number: 20240131167
    Abstract: Provided herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation. The disclosure also provides pharmaceutically acceptable compositions comprising compounds and methods for the treatment of EGFR mutant-related cancers.
    Type: Application
    Filed: October 30, 2023
    Publication date: April 25, 2024
    Applicant: BeiGene Switzerland GmbH
    Inventors: Bailin Lei, Huaqing Liu, Songzhe Han, Zhiwei Wang
  • BIFUNCTIONAL COMPOUNDS FOR DEGRADATION OF EGFR AND RELATED METHODS OF USE
    Publication number: 20240025902
    Abstract: Disclosed herein are bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation of mutant EGFR kinase, and methods of preparation and uses thereof.
    Type: Application
    Filed: September 29, 2021
    Publication date: January 25, 2024
    Inventors: Bailin LEI, Huaqing LIU, Songzhe HAN, Zhiwei WANG
  • INDOLINE COMPOUNDS AND DERIVATIVES AS EGFR INHIBITORS
    Publication number: 20230373960
    Abstract: Disclosed herein are novel pharmaceutically active compounds and their preparation methods. The compounds inhibit mutant EGFR and are useful in the treatment of oncological diseases.
    Type: Application
    Filed: September 22, 2021
    Publication date: November 23, 2023
    Inventors: Bailin LEI, Huaqing LIU, Songzhe HAN, Zhiwei WANG
  • DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
    Publication number: 20230265116
    Abstract: Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
    Type: Application
    Filed: July 15, 2021
    Publication date: August 24, 2023
    Inventors: Bailin LEI, Huaqing LIU, Songzhe HAN, Zhiwei WANG
  • DEGRADATION OF (EGFR) BY CONJUGATION OF EGFR INHIBITORS WITH E3 LIGASE LIGAND AND METHODS OF USE
    Publication number: 20230248834
    Abstract: Disclosed herein are novel bifunctional compounds formed by conjugating EGFR inhibitor moieties with E3 ligase Ligand moieties, which function to recruit targeted proteins to E3 ubiquitin ligase for degradation, and methods of preparation and uses thereof.
    Type: Application
    Filed: July 15, 2021
    Publication date: August 10, 2023
    Inventors: Bailin LEI, Huaqing LIU, Songzhe HAN, Zhiwei WANG